Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Annovis Bio Inc (ANVS)

Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,329
  • Shares Outstanding, K 26,503
  • Annual Sales, $ 0 K
  • Annual Income, $ -24,590 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 1.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.18

Options Overview Details

View History
  • Implied Volatility 715.60% (+133.18%)
  • Historical Volatility 89.33%
  • IV Percentile 83%
  • IV Rank 51.43%
  • IV High 1,372.26% on 02/12/25
  • IV Low 20.18% on 01/06/26
  • Expected Move (DTE 8) 2.15 (70.28%)
  • Put/Call Vol Ratio 0.14
  • Today's Volume 662
  • Volume Avg (30-Day) 346
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 13,248
  • Open Int (30-Day) 19,442
  • Expected Range 0.91 to 5.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.43
  • Growth Rate Est. (year over year) +232,425.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.70 +13.33%
on 01/20/26
4.14 -26.09%
on 01/08/26
-0.87 (-22.14%)
since 12/22/25
3-Month
1.89 +61.90%
on 11/04/25
5.50 -44.36%
on 11/28/25
+1.03 (+50.74%)
since 10/22/25
52-Week
1.11 +175.68%
on 04/09/25
5.50 -44.36%
on 11/28/25
-2.25 (-42.37%)
since 01/22/25

Most Recent Stories

More News
Annovis Announces Open-Label Extension Study for Parkinson's Disease Patients

Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The study aims to enroll 500 patients MALVERN, Pa., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Annovis...

ANVS : 3.06 (+6.25%)
Annovis to Host Corporate Update Webinar on January 28, 2026

MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.06 (+6.25%)
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group

MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.06 (+6.25%)
Annovis Announces Two Presentations at the CTAD 2025 Conference

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.06 (+6.25%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

AVAI : 0.7391 (-1.26%)
ANVS : 3.06 (+6.25%)
RXRX : 4.96 (+7.59%)
ZYME : 23.55 (-1.67%)
NTLA : 15.90 (+13.33%)
Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

MarketNewsUpdates News Commentary NEW YORK, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The advance anti-aging therapies market is expanding quickly fueled by a larger senior population and increased...

AVAI : 0.7391 (-1.26%)
ANVS : 3.06 (+6.25%)
RXRX : 4.96 (+7.59%)
ZYME : 23.55 (-1.67%)
NTLA : 15.90 (+13.33%)
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study

MALVERN, Pa., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for...

ANVS : 3.06 (+6.25%)
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients

Buntanetap significantly improves cognition in all Parkinson’s patients, with those exhibiting Alzheimer’s co-pathology showing a three-times greater response New data demonstrate reductions...

ANVS : 3.06 (+6.25%)
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative...

ANVS : 3.06 (+6.25%)
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program

All 84 clinical sites across the U.S. are fully activated, enrolling, and treating patients The first group of participants reached the 6-month treatment milestone The study is now 25% complete,...

ANVS : 3.06 (+6.25%)

Business Summary

Annovis Bio Inc. is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease, Parkinson's disease and Alzheimer's in Down Syndrome. Annovis Bio Inc. is headquartered in Berwyn, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 3.45
2nd Resistance Point 3.32
1st Resistance Point 3.19
Last Price 3.06
1st Support Level 2.93
2nd Support Level 2.80
3rd Support Level 2.67

See More

52-Week High 5.50
Fibonacci 61.8% 3.82
Fibonacci 50% 3.31
Last Price 3.06
Fibonacci 38.2% 2.79
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar